Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Dyne Therapeutics reported a net loss of $1.08 per share for Q2 2026, with R&D expenses rising to $152.2 million to support advancing clinical trials. The company strengthened its balance sheet, closing a public offering for approximately $405 million in net proceeds and securing a $400 million debt facility, extending its cash runway into Q2 2028. Operationally, the FDA accepted the BLA for z-rostudirsen in exon 51 DMD and granted Priority Review with a PDUFA target date of January 21, 2027. The company also initiated the Phase 3 FORZETTO trial for DMD and the Phase 3 HARMONIA trial for DM1, completing enrollment in the registrational expansion cohort for the latter.
Key figures
- Runway
- Q2 2028
- Net loss
- 178600000
- Pdufa date
- January 21, 2027
- Ga expenses
- 29500000
- Rd expenses
- 152200000
- Cash position
- 898500000
- Debt facility
- 400000000
- Offering price
- 20.5
- Shares offered
- 21045000
- Offering net proceeds
- 405000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.